Morning Overview on MSN
PerturbFate, a new AI, can now forecast how tens of thousands of mutations push cells toward cancer at once — pointing drug makers straight at the ones that matter
Melanoma kills roughly 8,000 Americans each year, and a stubborn share of those deaths trace back to the same problem: tumors ...
Morning Overview on MSN
A new tool called PerturbFate can now predict how thousands of genetic mutations drive disease at once — aimed squarely at cancer and Alzheimer’s
A melanoma cell can dodge a targeted drug in dozens of different ways, each driven by a different genetic mutation. But what ...
Adding a second checkpoint inhibitor to chemotherapy improves outcomes among patients with non–small cell lung cancer (NSCLC) who have STK11 and/or KEAP1 mutations, according to the authors of a new ...
In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...
Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen ...
Despite the significance of immune checkpoint inhibitors (ICIs) in solid tumor treatment, identifying ICI-sensitive populations remains a challenge. Mutations in DNA damage response (DDR) pathway ...
The BRAF mutation affects a small percentage of non-small cell lung cancer (NSCLC) cases, making the cancer more difficult to treat. In recent years, advances in treatment have helped to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results